ST Pharm to construct second oligonucleotide facility in Korea
The expansion is expected to make the company the largest CDMO in oligonucleotide production in 2025
South Korea's ST Pharm — an API CDMO — has announced plans to invest $126 million during the next three to four years in building a second oligonucleotide facility at its Banwol campus located in Ansan.
The company says the new facility will have four to six large production lines and a solvent recycling system, which will make the manufacturing process more environmentally friendly as well as help to reduce costs.
According to the company, the plant will offer customers efficiency by shortening the production period through a parallel cross-production process design.
Last year, ST Pharm decided to expand the capcity at its first site from 1.5 to 6.4 mole per year. Establishing a second oligonucleotide plant will provide a production capacity of 14 mole per year, which forecasts the company to become the world's largest (in terms of capacity) CDMO in oligonucleotide production in 2025.
The demand for raw materials and APIs is expected to surge if new blockbuster oligonucleotide drugs are approved for commercialisation from 2024. The company says the second manufacturing plant and production facilities will prepare it for this uptick in demand.
By 2030, ST Pharm says its oligonucleotide CDMO services will generate ₩1 trillion KRW, which will help it to become a global top 5 CDMO for mRNA and various next generation RNA therapies.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.